Development of high-performance magnetic chemiluminescence enzyme immunoassay for α-fetoprotein (AFP) in human serum

Clinica Chimica Acta

Volumn 393, Issue 2, 2008, Pages 90-94

  Wang, Xu ^a   Zhang, Qian Yun ^a,b   Li, Zhen Jia ^c   Ying, Xi Tang ^c   Lin, Jin Ming ^a  

^a TSINGHUA UNIVERSITY   (China)

^b BEIJING UNIVERSITY OF CHEMICAL TECHNOLOGY   (China)

^c Beijing Chemclin Biotech Co Ltd   (China)

Author keywords

Fetoprotein (AFP); Chemiluminescence enzyme immunoassay (CLEIA); Hepatocellular carcinoma (HCC); Magnetic particles (MPs)

Indexed keywords

ALKALINE PHOSPHATASE; ALPHA FETOPROTEIN; FLUORESCEIN ISOTHIOCYANATE; PROTEIN ANTIBODY;

ANALYTICAL PARAMETERS; ANTIBODY LABELING; ANTIGEN ANTIBODY COMPLEX; ARTICLE; CHEMOLUMINESCENCE; CROSS REACTION; HIGH PERFORMANCE MAGNETIC CHEMILUMINESCENCE ENZYME IMMUNOASSAY; HUMAN; IMMUNITY; LIGHT INTENSITY; MAGNETISM; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SEPARATION TECHNIQUE;

ALPHA-FETOPROTEINS; HUMANS; IMMUNOENZYME TECHNIQUES; LUMINESCENCE; MAGNETICS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY;

EID: 44449172893     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cca.2008.03.010     Document Type: Article

References (25)

1. Llovet J.M., Burroughs A., and Bruix J. Hepatocellular carcinoma. The Lancet 362 (2003) 1907-1917
2. Bosch X., Ribes J., and Borras J. Epidemiology of primary liver cancer. Semin Liver Dis 19 (1999) 271-285
3. Di Bisceglie A.M., Rustgi V.K., Hoofnagle J.H., et al. Hepatocellular carcinoma. Ann Intern Med 108 (1988) 390-401
4. Kew M.C., Dos Santos H.A., and Sherlock S. Diagnosis of primary cancer of the liver. Br Med J 4 (1971) 408-411
5. The Cancer of the Liver Italian Program (CLIP) investigators. A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients. Hepatology 28 (1998) 751-755
6. Mizejewski G.J. Alpha-fetoprotein structure and function: relevance to isoforms, epitopes, and conformational variants. Exp Biol Med 226 (2001) 377-408
7. Larcos G., Sorokopud H., Berry G., et al. Sonographic screening for hepatocellular carcinoma in patients with chronic hepatitis or cirrhosis: an evaluation. AJR Am J Roentgenol 171 (1998) 433-435
8. Bruix J., Sherman M., Llovet J.M., et al. Clinical management of hepatocellular carcinoma: conclusions of the Barcelona-2000 EASL Conference. J Hepatol 35 (2001) 421-430
9. Lamerz R, Hayes P, Hoffmann R-T, et al. National Academy of Clinical Biochemistry (NACB [l]). Guidelines for the use of tumor markers in primary liver cancer. Updated 2005. Accessed Aug 2007. Available at URL address: http://www.nacb.org/lmpg/tumor/chp3d_liver.pdf.
10. Fuji Y., Taketa K., Aoi T., et al. Increased serum levels of monosialo-alpha-fetoprotein in hepatocellular carcinoma and other malignancies. Tumour Biol 14 (1993) 319-324
11. Matsumoto Y., Suzuki T., and Asada I. Clinical classification of hepatoma in Japan according to serial changes in serum alpha-fetoprotein levels. Cancer 49 (1982) 354-360
12. Christensen R.L., Rea M.R.K.G., Crane J.P., et al. Implementation of a screening program for diagnosing open neural tube defects: selection, evaluation, and utilization of alpha-fetoprotern methodology. Clin Chem 32 (1986) 1812-1817
13. Nomura M., Imai M., Takahashi K., et al. Three-site sandwich radioimmunoassay with monoclonal antibodies for a sensitive determination of human alpha-fetoprotein. J Immunol Methods 58 (1983) 293-300
14. Wang W.K., Ho L.T., and Chiang Y. Space-resolved fluoroimmunoassay for quantifying α-fetoprotein in serum. Clin Chem 39 (1993) 1659-1661
15. Eduardo V.N., Eulália C.D.C., and Armando F. Adaptation of alpha-fetoprotein and intact human chorionic gonadotropin fluoroimmunometric assays to dried blood spots. Clin Chim Acta 360 (2005) 151-159
16. Zhang B., Zhang X., Yan H.H., et al. A novel multi-array immunoassay device for tumor markers based on insert-plug model of piezoelectric immunosensor. Biosens Bioelectron 23 (2007) 19-25
17. Guana G.J., Miao Y.Q., and Chen J.R. Prussian blue modified amperometric FIA biosensor: one-step immunoassay for α-fetoprotein. Biosens Bioelectron 19 (2004) 789-794
18. Liu Y.M., Mu H.B., Zheng Y.L., et al. Capillary electrophoretic immunoassay for alpha-fetoprotein with chemiluminescence detection. J Chromatogr B 855 (2007) 280-285
19. Zhang S.H., Zhang C., Xing Z., et al. Simultaneous determination of α-fetoprotein and free β-human chorionic gonadotropin by element-tagged immunoassay with detection by inductively coupled plasma mass spectrometry. Clin Chem 50 (2004) 1214-1221
20. Arakawa H., Ikegami T., Maeda M., et al. Chemiluminescent enzyme immunoassay for alpha-fetoprotein using β-D-galactosidase as label and 5-bromo-4-chloro-3-indolyl-β-D-galactopyranoside as substrate. J Biolumin Chemilumin 8 (1993) 135-139
21. Fu Z.F., Hao C., Fei X.Q., et al. Flow-injection chemiluminescent immunoassay for α-fetoprotein based on epoxysilane modified glass microbeads. J Immunol Methods 312 (2006) 61-67
22. Tudorache M., Zdrojewska I.A., and Emnéus J. Evaluation of progesterone content in saliva using magnetic particle-based immuno supported liquid membrane assay (m-ISLMA). Biosens Bioelectron 22 (2006) 241-246
23. Gong J.L., Liang Y., Huang Y., et al. Ag/SiO2 core-shell nanoparticle-based surface-enhanced Raman probes for immunoassay of cancer marker using silica-coated magnetic nanoparticles as separation tools. Biosens Bioelectron 22 (2007) 1501-1507
24. Tanaka T., and Matsunaga T. Fully automated chemiluminescence immunoassay of insulin using antibody-protein A-bacterial magnetic particle complexes. Anal Chem 72 (2000) 3518-3522
25. Zhao L.X., Lin J.-M., and Li Z.J. Comparison and development of two different solid phase chemiluminescence ELISA for the determination of albumin in urine. Anal Chim Acta 541 (2005) 199-207